The Department of Health and Social Care is taking forward the recommendation of the UK National Screening Committee to increase the use of digital pathology to examine body tissue samples as part of screening programmes.
Digital pathology will enable quicker and more accurate diagnosis by allowing digital review of tissue samples, facilitating remote reporting, and assisting clinicians in obtaining second opinions. The technology involves whole slide imaging, where high-resolution images of entire glass slides can be viewed and stored digitally. The decision to adopt this approach comes after successful trials demonstrating that digital microscopy is as effective as traditional methods. The rollout across the NHS is expected, with NHS England providing guidance on best practices. The UK National Screening Committee, an independent advisory body, plays a crucial role in guiding these screening initiatives. Digital pathology brings several benefits to both care providers and patients alike:
Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications, today announced the release of a groundbreaking product developed from Paige’s Pathology Foundation Model, Virchow. Built using one of the largest libraries of digitized images, utilizing unique computational resources provided by Microsoft Research, Paige has developed the first application that can detect cancer across more than 17 different tissue types including skin, lung, and the gastrointestinal tract, along with multiple rare tumor types and metastatic deposits.
Owkin, a Franco-American biotech company, announces a new collaboration with AP-HP, putting artificial intelligence at the service of oncology diagnosis. The Bicêtre AP-HP hospital, a pilot in digital pathology, is now positioning itself as a pioneer by using “RlapsRisk® BC”, [1] an innovative AI solution designed to help doctors assess patients' risk of relapse suffering from breast cancer. This initiative fully supports the ten-year national strategy to combat cancer, by offering healthcare professionals the cutting-edge tools necessary to improve patient care. With this partnership, Owkin strengthens its commitment to public hospitals in France.
Owkin, a French-American biotechnology company that applies artificial intelligence (AI) to drug discovery, development, and diagnostics, has announced that it has entered into a collaboration agreement with MSD, the trade name of Merck & Co Inc., Rahway NJ USA to develop and commercialize AI-powered digital pathology diagnostics for the EU market. Clinical trials have shown that the [...]
When pathologists examine tissues to diagnose a disease, some samples come from body fluids, such as bronchial washes, rather than from solid tissues. To analyze these liquid cytology samples, pathologists concentrate the cells and embed them in a paraffin block, called a cell block. However, the transparent matrix and sparse cells in cell blocks can make them challenging for digital slide scanners to fully capture in focus.
Aiforia has entered into an exclusive licensing agreement with the Mayo Clinic in the United States to globally commercialize an AI model that improves prediction of colorectal cancer recurrence. The AI model was developed in collaboration with the Mayo Clinic. The AI model identifies important histological features of colorectal cancer and provides a recurrence prediction estimate useful for colorectal cancer treatment decisions.
The Provincial Health Authority of Catania in Italy has selected Aiforia Technologies Plc as a partner for AI-assisted diagnostics in the anatomic pathology laboratory of Gravina Hospital.
Cristina González Gonzalo, Clinical Program Manager at Aiosyn, shares her experiences from the clinical validation of Aiosyn Mitosis Breast. Joining the team in May 2022, she played a crucial role in validating Aiosyn’s mitosis detection AI algorithm. In this interview, she provides insights into ensuring the study’s results are representative, discusses the challenges faced, and outlines her approach to coordinating collaboration with Radboud University Medical Center.
Owkin, a techbio company using artificial intelligence to accelerate precision medicine by discovering and developing new drugs and diagnostics and Cerba Path, the Cerba HealthCare’s network of pathologists, today announced a new partnership. The two companies will work together to integrate Owkin’s cutting-edge AI-driven diagnostics into Cerba Path’s routine digital workflows and further validate AI-based tools for precision medicine.
